Researchers may finally have identified a first-line treatment for hepatocellular carcinoma that is superior to the current standard. In a phase III trial, atezolizumab plus bevacizumab extended median progression-free survival and overall survival compared with sorafenib, and the combination was associated with a similar rate and severity of side effects as sorafenib.

中文翻译：

---

组合有望成为HCC的标准配置。

研究人员可能最终已经确定了优于当前标准的一线治疗肝细胞癌的方法。在一项III期临床试验中，与索拉非尼相比，阿特珠单抗联合贝伐单抗可延长中位无进展生存期和总生存期，并且该组合与索拉非尼具有相似的副作用发生率和严重程度。